Neoadjuvant Herceptin in Patients With Breast Cancer

NCT ID: NCT00133796

Last Updated: 2017-02-07

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2001-10-31
• Study Completion Date: 2007-04-30

Brief Summary

The purposes of this study are to better understand how Herceptin causes tumors to become smaller and to find out how effective Herceptin, together with chemotherapy, is in treating advanced breast cancer.

Detailed Description

We want to determine the effects of Herceptin and to determine its efficacy in women with HER-2 overexpressing advanced breast cancer. The end-points will include the comparison of an array of histologic and molecular markers from sequential core biopsies of primary breast cancers of patients receiving Herceptin.

The other aim of this study would be to determine clinical response to therapy with Herceptin and Taxotere.

Conditions

BREAST CANCER

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Heceptin

Herceptin administered to enrolled subjects

Group Type: EXPERIMENTAL

Herceptin

Intervention Type: DRUG

IV

Interventions

Herceptin

IV

Intervention Type: DRUG

Other Intervention Names

Trastuzumab

Eligibility Criteria

Inclusion Criteria

• All patients must be female.
• Informed consent must be signed.
• Women with locally advanced breast cancers or primary breast cancers with concomitant gross metastatic disease are eligible. Locally advanced cancers must be of clinical and/or radiologic size > 4 cm, and/or are deemed surgically inoperable.
• Her2/neu overexpressing tumors defined as HercepTest score of 3+, or >/= one-third of invasive tumor showing membranous staining, or fluorescence in situ hybridization (FISH) positive.
• Negative serum pregnancy test (bHCG) within 7 days of starting study, if of child-bearing potential.
• Kidney and liver function tests - all within 1.5 times of the institution's upper limit of normal.
• Performance status (World Health Organization [WHO] scale) < 2 and life expectancy > 6 months.
• Age > 18.
• No metastatic disease without concomitant primary breast cancer.
• No previous or current malignancies at other sites within the last 5 years, with exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.

Exclusion Criteria

• Pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential.
• Severe underlying chronic illness or disease.
• Cardiomyopathy or baseline left ventricular ejection fraction (LVEF) < 50%.
• Patients on other investigational drugs while on study.
• Severe or uncontrolled hypertension defined as blood pressure (BP) > 180/100 on three separate occasions.
• History of congestive heart failure.
• History of coronary arterial disease.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Genentech, Inc.

INDUSTRY

Sponsor Role: collaborator

Mothaffar Rimawi

OTHER

Sponsor Role: lead

Responsible Party

Mothaffar Rimawi

Medical Director

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Mothaffar Rimawi, MD

Role: PRINCIPAL_INVESTIGATOR

Baylor Breast Center, Baylor College of Medicine

Locations

Baylor Breast Center

Houston, Texas, United States

Countries

United States

Other Identifiers

H-10379

Identifier Type: -

Identifier Source: org_study_id